

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.


1. – 7. (Canceled)

8. (Previously Presented) A compound of the formula (I):

wherein



is



$R^1$  is  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$  or  $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$ ;

$R^2$  is hydrogen or alkyl;

$m$  is 0 or 1;

$X^1$  and  $X^3$  each is optionally substituted heteroaryl;

$X^2$  is  $-\text{CH}_2-$ ,  $-\text{CH}_2-\text{CH}_2-$ ,  $-\text{C}(=\text{O})-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{SO}-$ ,  $-\text{SO}_2-$ ,  $-\text{NH}-$ ,  $-\text{N}(\text{CH}_3)-$ ,  $-\text{C}(=\text{N}-\text{O}-\text{CH}_3)-$ ,  $-\text{N}=\text{N}-$ ,  $-\text{CH}=\text{CH}-$ ,  $-(\text{C}=\text{O})-\text{NH}-$ ,  $-\text{NH}-(\text{C}=\text{O})-$ ,  $-\text{CH}_2-\text{NH}-$ ,  $-\text{NH}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{O}-$ ,  $-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{S}-$ ,  $-\text{S}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{SO}_2-$ ,  $-\text{SO}_2-\text{CH}_2-$ ,  $-\text{SO}_2-\text{NH}-$  or  $-\text{NH}-\text{SO}_2-$ ;

a pharmaceutically acceptable salt, or a hydrate thereof.

9 - 10. (Canceled)

11. (Previously Presented) The compound according to claim 8 wherein at least one of  $X^1$  and  $X^3$  is optionally substituted thienyl or optionally substituted benzothienyl, the pharmaceutically acceptable salt, or the hydrate thereof.

12. (Previously Presented) The compound according to claim 8 wherein  $X^2$  is  $-CH_2-$ ,  $-S-$ ,  $-SO_2-$ ,  $-CH_2-O-$ ,  $-O-CH_2-$ ,  $-CH_2-S-$  or  $-S-CH_2-$ , the pharmaceutically acceptable salt, or the hydrate thereof.

13. (Previously Presented) The compound according to claim 8 wherein  $R^1$  is  $-CH_2-CH=CH-CH_2-CH_2-CH_2-COOH$ , and  $m$  is 0, the pharmaceutically acceptable salt, or the hydrate thereof.

14. (Previously Presented) A pharmaceutical composition which comprises a compound according to claim 8.

15 -18. (Canceled)

19. (Currently Amended) A method for treating a mammal to alleviate the pathological effects of asthma or nasal blockage which comprises administering to said mammal an effective amount of the compound according to claim 8.

20. (New) The compound according to claim 8 wherein  $X^1$  is optionally substituted thienyl, optionally substituted pyrrolyl, or optionally substituted benzothiazolyl, and  $X^3$  is optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted benzofuryl, optionally substituted furyl, or optionally substituted benzothienyl, the pharmaceutically acceptable salt, or the hydrate thereof.

21. (New) The compound according to claim 8 wherein  $X^3$  is  $-SO_2-$ ,  $-S-$ ,  $CH_2-$ ,  $CH_2-S-$ , or  $-S-CH_2-$ , the pharmaceutically acceptable salt, or the hydrate thereof.

22. (New) The compound according to claim 8 wherein  $R^1$  is  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOH}$ ,  $m$  is 0,  $X^1$  is optionally substituted thienyl, optionally substituted pyrrolyl, or optionally substituted benzothiazolyl,  $X^2$  is  $-\text{SO}_2-$ ,  $-\text{S}-$ ,  $-\text{CH}_2-\text{S}-$ , or  $-\text{S}-\text{CH}_2-$ ,  $X^3$  is optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted benzofuryl, optionally substituted furyl, or optionally substituted benzothienyl, the pharmaceutically acceptable salt, or the hydrate thereof.